Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D2 receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D3 receptor-blocking activities and weak 5-hydroxytryptamine-2C, α1 -, histamine H1 -, and muscarinic M1 -blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia.
Keywords: D3 receptor; blonanserin; delusion; dementia; hallucination.
© 2014 The Authors. Psychogeriatrics © 2014 Japanese Psychogeriatric Society.